Cagrilintide

Investigational · human trials incomplete.



Guide prepared November 13, 2026 · profile review dates retained

KEEP IN MIND Evidence applies to the studied formulation, route, population and outcome—not every product sharing a name.

01 What is it?

Cagrilintide is a long-acting amylin analog being studied for weight management. It has been tested alone and with semaglutide; evidence for the combination CagriSema belongs to a separate treatment record. [1]

02 Potential benefits

Long-acting amylin analog studied for weight management. Investigated alone and in combination with semaglutide. [1]

03 Evidence & its limits

The 2021 component trial measured bodyweight, safety, and tolerability; gastrointestinal and administration-site reactions were common. Results from CagriSema cannot be assigned entirely to cagrilintide or used to validate independently mixed products. Cagrilintide remains investigational. [1]

04 Risks & unknowns

Not FDA-approved. Combination benefits, adverse effects, and long-term outcomes remain under study. [1]

05 Status & scope

Not FDA-approved. [1]

06 The question to ask

Does the evidence match the exact product, route, condition and outcome being discussed? Check the full record and its review dates. This summary is selective; the product label and clinical assessment contain additional warnings and contraindications.

SOURCES / Tap a reference to open

[1] Full evidence record, references and review dates
[2] Randomized phase II dose-finding trial, 2021
[3] Cagrilintide with semaglutide phase 1b trial, 2021

Selective educational summary, not treatment or dosing advice. Existing profile review dates retained; no independent clinical review.